Found 6 results
Author Keyword [ Title(Desc)] Type Year
Filters: Author is Ho, Emily and First Letter Of Title is S  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
S
Zhang Z, Garzotto M, Davis EW, Mori M, Stoller WA, Farris PE, Wong CP, Beaver LM, Thomas GV, Williams DE et al..  2019.  Sulforaphane Bioavailability and Chemopreventive Activity in Men Presenting for Biopsy of the Prostate Gland: A Randomized Controlled Trial.. Nutr Cancer. :1-14.
Atwell LL, Zhang Z, Mori M, Farris P, Vetto JT, Naik AM, Oh KY, Thuillier P, Ho E, Shannon J.  2015.  Sulforaphane Bioavailability and Chemopreventive Activity in Women Scheduled for Breast Biopsy.. Cancer Prev Res (Phila). 8(12):1184-1191.
Myzak MC, Hardin K, Wang R, Dashwood RH, Ho E.  2006.  Sulforaphane inhibits histone deacetylase activity in BPH-1, LnCaP and PC-3 prostate epithelial cells.. Carcinogenesis. 27(4):811-9.
Myzak MC, W Dashwood M, Orner GA, Ho E, Dashwood RH.  2006.  Sulforaphane inhibits histone deacetylase in vivo and suppresses tumorigenesis in Apc-minus mice.. FASEB J. 20(3):506-8.
Abbas A, J Hall A, Patterson WL, Ho E, Hsu A, Al-Mulla F, Georgel PT.  2016.  Sulforaphane modulates telomerase activity via epigenetic regulation in prostate cancer cell lines.. Biochem Cell Biol. 94(1):71-81.
Myzak MC, Tong P, Dashwood W-M, Dashwood RH, Ho E.  2007.  Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects.. Exp Biol Med (Maywood). 232(2):227-34.